| PATENT NUMBER | This data is not available for free |
| PATENT GRANT DATE | March 25, 2003 |
| PATENT TITLE |
Method for producing purified hematinic iron-saccharidic complex and product produced |
| PATENT ABSTRACT |
A method for separating and purifying the active hematinic species present in iron-saccharidic complexes including sodium ferric gluconate complex in sucrose, ferric hydroxide-sucrose complex and ferric saccharate complex and others of similar form and function, based on separation of the iron-saccharidic complex from one or more excipients and, preferably, lyophilization. Separation of the iron-saccharidic complex permits its analytical quantification; further concentration or purification as a new and useful product; preparation of redesigned formulations for new and useful pharmaceuticals; and/or lyophilization. The ability to separate the iron-saccharidic complex responsible for hematinic function, including its lyophilized form, also provides a means for preparing analytical material to verify and validate its pharmacological integrity, patient safety and clinical performance, as well as analytical monitoring, standardization and quality control inspection over hematinic manufacturing processes and establishment of standards for use therewith. |
| PATENT INVENTORS | This data is not available for free |
| PATENT ASSIGNEE | This data is not available for free |
| PATENT FILE DATE | October 31, 2001 |
| PATENT REFERENCES CITED |
Rao et al. "Fe(III) Complexes of D-Glucose and D-Fructose." Biometals, vol. 7, pp. 25-29, 1994.* Geetha et al. "Transition-metal Saccharide Chemistry: Synthesis, Spectroscopy, Electrochemistry and Magnetic Susceptibility Studies of Iron(III) Complexes of Mono- and Disaccharides." Carbohydrate Research. vol. 271, pp. 163-175, 1995.* Rao et al. "Solution Stability of Iron-Saccharide Complexes." Bioorganic and Medicinal Chemistry Letters. vol. 2, No. 9, pp. 997-1002, 1992.* Rao et al. "Transition Metal Saccharide Chemistry and Biology: Syntheses, Characterization, Solution Stability and Putative Bio-relevant Studies of Iron-Saccharide Complexes." Inorganica Chimica Acta. vol. 297, pp. 373-382, Jan. 2000.* Zapalis, C. and R.A. Beck, 1985, "Food Chemistry and Nutritional Biochemistry," Chapter 6, John Wiley & Sons, pp. 315-321. "Raising the Bar for Quality Drugs", pp. 26-31, Chemical and Engineering News, American Chemical Society, Mar. 19, 2001. "Principles of Food Science", edited by O.R. Fennema, "Part II, Physical Principals of Food Preservation", M. Karel, et al., pp. 237-263, Marcel Dekker, Inc. 1975. Encyclopedia of Food Science, edited by M.S. Peterson, et al., "Water Activity in Relation to Food", D.H. Chou, pp. 852-857, Avi Publ. Co., Inc., 1978. C.M. Smales, D.S. Pepper, and D.C. James, 2000, "Mechanisms of protein modification during model antiviral heat-treatment bioprocessing of beta-lactoglobulin variant A in the presence of sucrose," Biotechnol. Appl. Biochem., Oct., 32 (Pt. 2) 109-119. Hodge, J.E. and E.M. Osman, 1976, Chapter 3, in "Food Chemistry," O.R. Fennema Ed., Marcel Dekkar, New York, pp. 92-96. Zapsalis C. and R.A. Beck, 1985, "Food Chemistry and Nutritional Biochemistry," Chapter 10, John Wiley & Sons, pp. 588-591. R. Dreywood, "Qualitative Test for Carbohydrate Material," Indus. and Eng. Chem., Anal. Ed., 18:499 (1946). J.E. Hodge and B.T. Hofreiter, "Determination of Reducing Sugars and Carbohydrates," Methods Carbohydrate Chem., 1:384-394 (1962). C. Zaphalis and R.A. Beck,"Food Chemistry and Nutrional Biochemistry," Chapter 6, John Wiley & Sons, pp. 353-354 (1985). P. Wyatt, Light scattering and absolute characterization of macromolecules, Analytica Chimica Acta. (1993) 272:1-40. Zapsalis and Beck, Food Chemistry and Nutrional Biochemistry, 1985, Chapter 1, pp. 23-26. "Freeze Drying", van Nostrand's Scientific Encyclopedia, Eighth Edition, pp. 1382-1342, 1995. |
| PATENT PARENT CASE TEXT | This data is not available for free |
| PATENT CLAIMS |
What is claimed is: 1. A method for monitoring an iron-saccharidic complex product produced in a manufacturing process, said complex comprising at least one active hematinic species, wherein said monitoring is conducted during a time selected from the group consisting of: (a) during the manufacturing process for said complex; (b) at the completion of the manufacturing process for said complex; and (c) following manufacturing of said complex, said method comprising (1) analyzing said complex to obtain an analytical response characteristic of the at least one active hematinic species in said complex and (2) comparing the analytical response of said at least one active hematinic species to a standard corresponding to said at least one species. 2. The method of claim 1 wherein said time following manufacturing of said complex is from about one week to about five years. 3. The method of claim 1 wherein said analytical response is obtained using at least one analytical method selected from the group consisting of: light scattering enhanced liquid chromatography; ultraviolet spectroscopy; visible spectroscopy; combined ultraviolet and visible spectroscopy; ultraviolet spectroscopy using photodiode arrays, visible spectroscopy using photodiode arrays and combined ultraviolet and visible spectroscopy using photodiode arrays; infrared spectroscopy, electron spin resonance; pulse polarography; energy dispersive X-ray analysis; circular dichroism and optical rotatory dispersion; fluorescent spectroscopy; polarimetry; pyrolysis mass spectroscopy; nuclear magnetic resonance spectroscopy; differential scanning calorimetry; liquid chromatography-mass spectroscopy; matrix assisted laser desorption/ionization-mass spectrometry; capillary electrophoresis; inductively-coupled plasma spectrometry; atomic absorption; electrochemical analysis; analysis utilizing radioactive isotopes including radioactive iron; antibodies to hematinic substances; retained solids following filtration through a membrane filter having porosity in the range of from about 0.02 to about 0.45 microns; high pressure liquid chromatography coupled with light scattering; and high pressure liquid chromatography coupled with light scattering and including a mass sensitive detector. 4. The method of claim 3 wherein said analytical method is light scattering enhanced liquid chromatography. 5. The method of claim 3 wherein at least one of said analytical methods is employed to determine at least one characteristic of a hematinic composition comprising purified iron-saccharidic complex during the manufacture of said composition and at the time of completion of manufacturing said composition and, optionally, at one or more times thereafter to verify that said at least one characteristic of said composition at the time of completion of manufacturing or at one or more times thereafter is substantially unchanged from a value or appearance of said characteristic during manufacturing of said composition. 6. The method of claim 1 wherein said at least one active hematinic species is monitored using high pressure liquid chromatography coupled with light scattering analysis or high pressure liquid chromatography coupled with light scattering analysis and including a concentration sensitive detector. 7. The method of claim 1 including the step of first isolating said at least one active hematinic species before obtaining said analytical response wherein said at least one active hematinic species is selected from the group consisting of sodium ferric gluconate complex in sucrose, ferric-hydroxide sucrose complex and ferric saccharate complex. 8. The method of claim 1 wherein said monitoring is conducted using at least one method selected from the group consisting of light scattering analysis in combination with a concentration sensitive detector, atomic absorption, X-ray analysis, electrochemical analysis, electron spin resonance, mass spectroscopy and ultracentrifugation, said monitoring being capable of indicating the presence of iron aggregate. 9. The method of claim 8 wherein said iron aggregate is comprised substantially of iron other than iron-saccharidic complex. 10. The method of claim 9 wherein said iron aggregate has a average formula weight of from about 200,000 to about 3,000,000 Daltons. 11. The method of claim 8 wherein said monitoring is used to calculate an occurrence ratio for iron other than iron-saccharidic complex and wherein said occurrence ratio is less than or equal to about 0.5. 12. A method for purifying a composition comprising iron-saccharidic complex and diluent, said complex comprising at least one active hematinic species and at least one excipient, said iron-saccharidic complex suitable for parental administration, comprising: (1) substantially separating said at least one active hematinic species from said at least one excipient; and optionally, (2) freeze drying said at least one active hematinic species. 13. The method of claim 12 wherein said at least one excipient comprises a non-hematinically active component. 14. The method of claim 13 wherein said at least one non-hematinically active component is selected from the group consisting of iron-saccharidic complex synthesis reaction by-products, unreacted iron-saccharidic complex synthesis starting materials, iron-saccharidic complex degradation by-product, waste glucans, polyglucans, saccharidic lactones, solvent and diluent. 15. The method of claim 12 further including step (2). 16. The method of claim 15 wherein freeze drying comprises the following steps: (1) said composition comprising said active hematinic species and diluent is frozen to a temperature selected from the group consisting of less than its eutectic point and less than its glass transition temperature thereby forming ice and providing an ice interface temperature; (2) an ice condensing surface capable of reaching temperatures at least about 20.degree. C. colder than said ice interface temperature is provided; (3) said frozen composition is present in an enclosure in which there is provided a vacuum capable of evacuation to an absolute pressure of from about 0.5 to about 10 Pa; and, (4) said frozen composition is exposed to a source of thermal energy sufficient to cause frozen water present to sublime to the vapor state and freeze on said ice condensing surface. 17. The method of claim 16 wherein: (1) said composition comprising said active hematinic species and diluent is frozen below its eutectic point; (2) said ice condensing surface is at a temperature of less than about -40.degree. C.; (3) said vacuum is at an absolute pressure of from about 1 Pa to about 8 Pa; and, (4) said source of thermal energy is controlled at from about -60.degree. C. to about +65.degree. C. 18. The method of claim 12 wherein said step of substantially separating comprises treating said composition by passing said composition through a chromatographic column and separating the column eluate into fractions. 19. The method of claim 18 wherein said column is selected from the group consisting of a high pressure liquid chromatography column and a size exclusion chromatography column, each column comprising a stationary phase. 20. The method of claim 19 wherein said stationary phase in said size exclusion chromatography column comprises crosslinked dextran. 21. The method of claim 20 wherein in addition to said at least one active hematinic species said composition further comprises an iron aggregate having a molecular weight higher than said at least one active hematinic species and said separating further comprises: (1) identifying an elution composition profile of said composition, said elution profile comprising at least a first eluate comprising said iron aggregate, a second eluate comprising the at least one active hematinic species of said iron-saccharidic complex and a third eluate comprising excipients having a molecular weight lower than said at least one active hematinic species; and (2) separating said first and third eluates from said second eluate. 22. The method of claim 21 wherein said elution composition profile is determined using at least one detector selected from the group consisting of a laser light scattering detector, an ultraviolet-visible light transmission detector, a visible light detector for detection at one or more defined wavelengths and a refractive index detector. 23. A method for producing a hematinic composition having improved storage stability using the method of either claim 12 or claim 17. 24. A method for purifying a composition comprising iron-saccharidic complex and diluent, said complex comprising at least one active hematinic species and at least one excipient, comprising: (1) substantially separating said at least one active hematinic species from said at least one excipient; and optionally, (2) freeze drying said at least one active hematinic species, wherein said step of substantially separating comprises treating said composition by passing said composition through a chromatographic column and separating column eluate into fractions, at least one of said fractions comprising said active hematinic species. -------------------------------------------------------------------------------- |
| PATENT DESCRIPTION |
BACKGROUND OF THE INVENTION The present invention relates to therapeutically active iron-containing species including parenteral hematinic pharmaceuticals. For purposes of the present invention a "hematinic" means a compound or composition comprising iron in a form that tends to increase the amount of hemoglobin in the blood of a mammal, particularly in a human. While such compounds can be broadly characterized as iron-carbohydrate complexes, which can include dextrans, the present invention is directed to the generic subclass known as iron-saccharidic complexes and includes such species as sodium ferric gluconate complex in sucrose (SFGCS), ferric hydroxide-sucrose complex (FHSC) and/or others characterized as iron saccharates. For purposes of the present invention, such active iron-containing species are referred to generically as iron-saccharidic complexes or active hematinic species (AHS). The term "complex" may have alternate meanings in various contexts in the related art. In one aspect, the term complex may be used to describe the association between two or more ions to form a relatively low molecular weight non-polymeric composition which exists singly under a given set of conditions. This type of "complex" has been referred to as a "primary complex". An alternate manner in which this term is used is to describe an association or agglomeration of a plurality of primary complexes into a large macromolecule, or "secondary complex." For purposes of the present invention, the latter agglomerates are also referred to herein as macromolecules. For the purposes of the present invention, such macromolecules or secondary complexes are identified as "complexes" and are referred to simply as complexes. As an example of the above distinction, ferrous gluconate is a composition comprising divalent iron ions and gluconate anions. A divalent iron ion and two gluconate anions form a primary complex of relatively low molecular weight (about 450 Daltons) and primary complexes of this type do not become agglomerated into macromolecules when dissolved into an aqueous medium. Ferrous gluconate, therefore, is a not composition which falls within the scope of the term "complex" herein. Ferric gluconate, however, does exist as a complex as that term is used herein because primary complexes of trivalent iron ions and gluconate anions agglomerate to form large macromolecules (and can have molecular weights of from about 100,000 to about 600,000 Daltons, or more). Several embodiments of therapeutically active ferric iron compounds are commercially available, as will be described below. For purposes of the present invention, the term "excipients" means non-hematinically active components, including synthesis reaction by-products and unreacted starting materials, degradation by-products, diluents, etc. present in admixture with therapeutically active iron-containing species such as iron-saccharidic complexes. Iron deficiency anemia is a blood disorder that can be treated using various therapeutic preparations containing iron. These preparations include simple iron salts such as ferrous sulfate, ferrous gluconate, ferrous fumarate, ferrous orotate and others. If the use of such orally administered substances fails to ameliorate iron deficiency, the next level of treatment includes parenteral iron administration. Depending on a patient's clinical status, parenteral administration of polyglucan or dextran-linked iron may serve as an effective therapeutic iron-delivery vehicle. Intramuscular injection or intravenous routes may be used to administer these iron dextrans; commercial examples of such products include those having trade names such as "Imferon", and "INFeD". Various clinical conditions that require parenteral iron have shown the practical hematinic value of iron dextrans. The use of iron dextrans is tempered by idiosyncrasies in their synthesis, manufacturing and patient responses such as hypersensitivity. These effects may be exhibited as a severe allergic response evident as anaphylaxis or symptoms as minor as transient itching sensations. Whether such allergic or other adverse effects are due to individual patient sensitivity to the active ingredient or to byproducts, impurities or degradation products in the parenteral solution has not been established. As an alternative to iron dextrans, iron-saccharidic complexes are regarded herein as non-dextran hematinics. Whereas the iron dextrans comprise polymerized monsaccharidic residues, the iron-saccharidic complexes of the present invention are characterized by the substantial absence of such polymerized monosaccharides. Iron-saccharidic complexes are commercially available, for example, under the tradename Ferrlecit, which is identified as sodium ferric gluconate complex in sucrose (SFGCS). The manufacturer states that the structural formula of the product is considered to be [NaFe.sub.2 O.sub.3 (C.sub.6 H.sub.11 O.sub.7) (C.sub.12 H.sub.22 O.sub.11) .sub.5 ].sub.n, where n is about 200, and as having an apparent molecular weight of 350,000.+-.23,000 Daltons. However, it is noted that, based on the published structural formula just recited, the formula weight should be significantly higher, 417,600 (although, as published, the formula is difficult to accurately interpret). Furthermore, the commercial hematinic composition comprises 20% sucrose, wt./vol. (195 mg/mL) in water. The chemical name suggests that therapeutic iron (Fe) in this form is pharmacologically administered as the oxidized ferric form Fe(III) as opposed to the reduced ferrous Fe(II) form. Owling to the charged oxidation state of Fe(III) it has been suggested that gluconic acid (pentahydroxycaproic acid, C.sub.6 H.sub.12 O.sub.7) also exists in a coordination complex or ligand form in a sucrose solution. For purposes of the present invention it is to be understood that the chemistry of gluconate, whether held in a ligand complex with Fe(III) or not, does not exempt it from interactions with other carbohydrates that may be present, such as sucrose. Thus, use of the term iron-saccharidic complex will be understood to indicate the existence of a nonspecific and imprecise structure where ionized-gluconic acid (gluconate) and sucrose molecules are tenuously associated by various bonding interactions to give a molecular scaffolding that incorporates Fe(III). Another non-dextran hematinic of the present invention is compositionally described as ferric hydroxide-sucrose complex (FHSC). This parenteral hematinic is commercially available under the tradename "Venofer". As with SFGCS, the descriptive name suggests a form of ferric iron, Fe(III), that is present in a spatial complex with sucrose or some derivative of sucrose. Therefore, non-dextran, iron-saccharidic complexes of the present invention include SFGCS, FHSC and mixtures thereof. These iron delivery vehicles include an iron-containing structural complex that, for purposes of the present invention, is designated the active hematinic species (AHS). For purposes of the present invention, the term AHS is used interchangeably with iron-saccharidic complex, saccharidic iron delivery vehicle, and iron saccharate. The term "saccharate" or "saccharidic" is employed to generically describe iron atom interactions with another individual molecule or its polymers that display a saccharose group structurally identified as --CH(OH)--C(O)-- The simplest occurrence of the saccharose group is where the two terminal positions in a standard Fischer molecular projection model of a molecule appear as an ald- or a keto-group respectively designated as: (--CH(OH)--CHO) or (--CHO--CH.sub.2 OH). This nomenclature format is also described in Zapsalis, C. and R.A. Beck, 1985, "Food Chemistry and Nutritional Biochemistry," Chapter 6, John Wiley & Sons, pp. 315-321 (incorporated herein by reference to the extent permitted). Such groups and their first oxidation or reduction products occur in molecules recognized as monosaccharides that contain carbon atoms with hydrogen and oxygen in the same ratio as that found in water. By way of example, the aldose sugar known as glucose would have gluconic acid as a first oxidation product and glucitol, also known as sorbitol, as a first reduction product. Both the original monosaccharide represented by the model of glucose and its possible reaction products retain evidence of the characteristic saccharide group in an oxidized or reduced form. While these structural variations exist, both remain recognized as monosaccharides and carbohydrates. In practical nomenclature, the oxidized version of the saccharose group exhibits a carboxyl group which under the appropriate pH conditions will allow it to ionize according to its unique ionization constant and pK.sub.a value. When ionized, the oxidized saccharose group is denoted as a "saccharate" or it can be generically described as a saccharidic acid where the ionizable proton remains with the oxidized saccharose group. If the ionized carboxyl group of the saccharose group is associated with a cation such as sodium, a saccharidic acid salt is formed. For example, oxidation of glucose gives gluconic acid and the sodium salt of this saccharidic acid is sodium gluconate. Similarly, where a ferrous (FeII) cation is electrostatically associated with the carboxyl group of gluconic acid, ferrous gluconate results. Monosaccharides that are aldoses commonly undergo oxidation to give their saccharidic acid equivalents or, when ionized, monosaccharate forms may interact with selected cations having valence states of +1 to +3. Glyceraldehyde is the simplest structure that demonstrates such an ald- group while dihydroxyacetone serves as a corresponding example of a keto-group. Practical extensions of such structures with six carbon atoms account for the descriptive basis of two carbohydrate classifications, one form being aldoses and the other ketoses. Aldoses and ketoses are respectively represented by monosaccharides such as glucose or fructose. With many possible intra- and intermolecular reaction products originating from monosaccharides, including the glucose oxidation product known as gluconic acid, efforts to complex iron with saccharates can produce an AHS. For purposes of the present invention, AHS is considered to be a more chemically complex embodiment of hematinic iron than suggested by the generic descriptor sodium ferric gluconate complex in sucrose (SFGCS) or ferric hydroxide-sucrose complex (FHSC), and therefore, designations including iron-saccharidic complex or saccharidic-iron delivery vehicle or saccharidic-iron are used interchangeably with AHS. Consequently, intra- and inter-molecular reactions or associations from reactions of monosaccharides with iron during hematinic syntheses, can coincidentally produce a wide variety of structural species with hematinic properties that are encompassed within the present invention. Typically iron-dextrans are provided for delivery of up to 100 mg Fe(III)/2.0 milliliter (mL) of injectable fluid, whereas iron-saccharidic complexes can provide 50-120 mg of Fe(III)/5.0 mL volume as commercially prepared in a single dose. As made, many of these iron-saccharidic complex products contain 10-40% weight-to-volume occurrences of non-hematinic excipients as well as synthesis reaction by-products. While some hematinic agents have an established compendial status under the aegis of the United States Pharmacopoeia (USP) or National Formulary (NF), iron-saccharidic complexes have no acknowledged compendial reference, standardized molecular identity characteristics or documented molecular specificity unique to the active hematinic species. This suggests that the iron-delivery vehicle in non-dextran hematinics such as SFGCS or FHSC has not previously been adequately purified and separated from manufacturing excipients so as to permit detailed characterization. Consequently, there has not been developed a benchmark reference standard or an excipient-free analytical quality control index capable of characterizing one desirable hematinic agent from others having uncertain characteristics. Since the 1975 merger of the USP with the NF to produce the USP-NF compendial guidelines for drugs, standard identities and analytical protocols have been developed for over 3,800 pharmaceuticals while 35% of marketed pharmaceuticals are still not included in the USP-NF. Hematinic pharmaceuticals such as SFGCS and FHSC fall within this latter category. This issue has been recently addressed in "Raising the Bar for Quality Drugs", pp. 26-31, Chemical and Engineering News, American Chemical Society, Mar. 19, 2001. As in the case of immune and anaphylactic responses elicited by specific antigens, a fine line of molecular specificity and compositional differentiation can separate a no-adverse-effect level for one hematinic's active molecular structure and excipients from another that may induce such adverse reactions. Thus, there is a need to identify features that document one hematinic's safe and effective characteristics from others where little is known about the iron-delivery vehicle, excipients representing synthesis reagent overage or byproducts of hematinic synthesis reactions. Furthermore, there are no long-term detailed sample archives or data using modern analytical instrumentation that meaningfully characterize the chemical nature of even the safest parenteral iron-saccharidic complexes. Moreover, correlation between variations in normal hematinic manufacturing conditions and their consequential effects identifiable as changes in the chemical structure of a released pharmacological agent have not been identified. The methods of the present invention can address such issues. The present invention can also provide an analytical basis for a routine protocol in order to fingerprint and characterize iron-saccharidic complexes such as SFGCS, FHSC and others as well as discriminate between competing products and structural transformations exhibited by an individual product. The need to characterize an AHS is also reflected in the quality control demands of manufacturing processes, particularly where endothermic conditions and heat transfer issues can affect final product quality. Whatever the proprietary synthesis process, possible heat-driven or Strecker reaction byproducts in some commercially released non-dextran products suggest that hematinic product formation is contingent on at least some controlled heat-input during the course of manufacturing. Such excipients would not occur if process temperatures less than about 50.degree. C. were unnecessary. It follows then, that product quality is related, to some extent, to issues of heat transfer rates and duration of heat exposure. Where products are especially sensitive to heat processing conditions, knowledge of excipient profiles can also provide significant insight to the product quality of the active pharmacological substance. In other words, monitoring the safe and effective pharmacological agent can also be indicated by the nature and constancy of excipient occurrence in a drug as released into the marketplace. Analytical studies on iron-saccharidic complexes, including AHS and its coexisting excipients are hampered by factors of low concentration, molecular interactions, over-lapping analytical signals and so on. For both SFGCS and FHSC, analytical challenges include high concentrations of hydrophilic excipients, including excess reactants and reaction and post-reaction byproducts, from which their respective AHS's have not previously been isolated or reported in terms of their individual properties. Reference standards for pharmaceuticals need to abide by practical protocols that are routinely achievable using methods that are analytically discriminating and able to be verified and validated. There is a continuing need for such methods and application of the present invention can facilitate compliance with such protocols as well as verifying manufacturing consistency and product stability. SUMMARY OF THE INVENTION A method for monitoring an iron-saccharidic complex product comprising at least one active hematinic species, wherein such monitoring is conducted during a time selected from the group consisting of: (a) during the manufacturing process for the complex; (b) at the completion of the manufacturing process for the complex; and (c) following manufacturing of the complex, the method comprising comparing the analytical response of the at least one active hematinic species to a standard corresponding to the at least one species. Such a standard can be obtained, for example, by purifying a hematinic composition comprising an iron-saccharidic complex in a diluent, typically water, the complex comprising at least one active hematinic species and at least one excipient. The purifying method comprises: (1) separating the at least one active hematinic species from the at least one excipient; and optionally, (2) freeze drying the at least one active hematinic species. Separation can be accomplished, for example, by using a chromatographic column. Various sophisticated and powerful analytical tools can be applied to the purified standard, thereby allowing for the monitoring of production processes and stability of the resulting product, as well as facilitating the development of new and improved hematinics. Furthermore, the present invention provides an iron-saccharidic complex selected from the group consisting of ferric hydroxide complex in sucrose, sodium ferric gluconate complex in sucrose and ferric saccharate complex wherein the complex is substantially free of excipients. Following manufacturing, the substantially excipient free complex, in a parenteral composition or as a freeze dried product, may be storage stable for extended periods; for example, up to five years or more. |
| PATENT EXAMPLES | available on request |
| PATENT PHOTOCOPY | available on request |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |